Strengthening the FDA’s Enforcement of Reporting Requirements

December 7, 2021, Vol 326, No. 21, Pages 2105-2223


Strengthening the FDA’s Enforcement of Reporting Requirements
Reshma Ramachandran, MD, MPP; Christopher J. Morten, JD, PhD; Joseph S. Ross, MD, MHS
free access
JAMA. 2021;326(21):2131-2132. doi:10.1001/jama.2021.19773
This Viewpoint discusses ways in which the FDA could harness its enforcement tools to bring important missing clinical trial results information to light and demonstrate its commitment to protecting patients through clinical trial transparency.